Biostockclub, yeah interesting that biib seems to be betting on both teams(theories) LOL. Should be upsetting to biib investors that have heard their plaque pitch for years!
Regarding biib confidence in aducanumab, I say, and hope the FDA says, run another trial and prove it.
Cherry picking, a term used frequently around here, might be called on biib. But after thinking about it, maybe it is a term that is not valid to use, for drugs in early trials. The reason being that early on, companies are not sure of what doses to use, what results will be, or strength of response. Biib might have found some dosage for some subset of their patients where there may be actually an improvement. Not cherry picking, just data analysis. Ok, now it is time for them to prove it. Let's see how strong the signal ultimately is, and how large the improvement population actually is. I would say they have a lot of work to do on that, at best.
Anavex on the other hand has strong signals. Can we say it was cherry picking? No just data analysis! Anavex is trying to determine dosages, establish concentrations, and determine populations affected and why. They were small population trials, given, but now anavex is using larger pops and refining parameters.
We seem to have a stronger signal than they had, and it looks like we are farther along the road to approval and understanding our a2-73 drug than biib is with aducanumab.
It seems like biib is trying to get around the system by pressuring/challenging fda to approve aaducanumab, and not prove the signal that they claim to see...by running a trial. Lol fda is being tested/trialed now! They are supposed to be the impartial judge/referee...we will see if they pass the trial! And not succumb to BP.
Thanks for the report bio!
Just passing along my thoughts on biib.
